Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beta Bionics Inc (BBNX)

Beta Bionics Inc (BBNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 599,180
  • Shares Outstanding, K 44,025
  • Annual Sales, $ 65,120 K
  • Annual Income, $ -54,760 K
  • EBIT $ -69 M
  • EBITDA $ -66 M
  • 60-Month Beta N/A
  • Price/Sales 6.13
  • Price/Cash Flow N/A
  • Price/Book 2.09

Options Overview Details

View History
  • Implied Volatility 231.67% (+56.17%)
  • Historical Volatility 145.43%
  • IV Percentile 90%
  • IV Rank 92.60%
  • IV High 244.99% on 02/06/26
  • IV Low 65.12% on 12/26/25
  • Expected Move (DTE 29) 3.59 (26.65%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 26
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 1,816
  • Open Int (30-Day) 1,364
  • Expected Range 9.87 to 17.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.51
  • Number of Estimates 4
  • High Estimate -0.44
  • Low Estimate -0.54
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +1.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.33 +18.80%
on 02/18/26
19.03 -29.27%
on 01/20/26
-5.04 (-27.24%)
since 01/16/26
3-Month
11.33 +18.80%
on 02/18/26
32.71 -58.85%
on 11/26/25
-14.26 (-51.44%)
since 11/19/25
52-Week
8.89 +51.41%
on 04/07/25
32.71 -58.85%
on 11/26/25
-8.35 (-38.29%)
since 02/19/25

Most Recent Stories

More News
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management...

BBNX : 13.46 (-1.10%)
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results...

BBNX : 13.46 (-1.10%)
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 13.46 (-1.10%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are...

BBNX : 13.46 (-1.10%)
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss...

BBNX : 13.46 (-1.10%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised...

BBNX : 13.46 (-1.10%)
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 13.46 (-1.10%)
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 13.46 (-1.10%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised...

BBNX : 13.46 (-1.10%)
Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to...

BBNX : 13.46 (-1.10%)

Business Summary

Beta Bionics Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of solutions. Beta Bionics Inc. is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 14.96
2nd Resistance Point 14.39
1st Resistance Point 13.92
Last Price 13.46
1st Support Level 12.88
2nd Support Level 12.31
3rd Support Level 11.84

See More

52-Week High 32.71
Fibonacci 61.8% 23.61
Fibonacci 50% 20.80
Fibonacci 38.2% 17.99
Last Price 13.46
52-Week Low 8.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar